Format

Send to

Choose Destination
Front Immunol. 2017 Dec 4;8:1597. doi: 10.3389/fimmu.2017.01597. eCollection 2017.

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Author information

1
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
2
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
3
Department of Hematology, JiangSu Province Hospital, The First Affiliated Hospital of NanJing Medical University, NanJing, JiangSu Province, China.
4
Graduate School of Biomedical Science, The University of Texas Health Science Center at Houston, Houston, TX, United States.

Abstract

PD-1-PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1-PD-L1 axis is affected by the complex immunologic regulation network, and some CD8+ T cells can enter an irreversible dysfunctional state that cannot be rescued by PD-1/PD-L1 blockade. In most advanced cancers, except Hodgkin lymphoma (which has high PD-L1/L2 expression) and melanoma (which has high tumor mutational burden), the objective response rate with anti-PD-1/PD-L1 monotherapy is only ~20%, and immune-related toxicities and hyperprogression can occur in a small subset of patients during PD-1/PD-L1 blockade therapy. The lack of efficacy in up to 80% of patients was not necessarily associated with negative PD-1 and PD-L1 expression, suggesting that the roles of PD-1/PD-L1 in immune suppression and the mechanisms of action of antibodies remain to be better defined. In addition, important immune regulatory mechanisms within or outside of the PD-1/PD-L1 network need to be discovered and targeted to increase the response rate and to reduce the toxicities of immune checkpoint blockade therapies. This paper reviews the major functional and clinical studies of PD-1/PD-L1, including those with discrepancies in the pathologic and biomarker role of PD-1 and PD-L1 and the effectiveness of PD-1/PD-L1 blockade. The goal is to improve understanding of the efficacy of PD-1/PD-L1 blockade immunotherapy, as well as enhance the development of therapeutic strategies to overcome the resistance mechanisms and unleash the antitumor immune response to combat cancer.

KEYWORDS:

MSI; PD-1; PD-L1; TMB; biomarker; combination immunotherapy; immune checkpoint blockade; resistance mechanism

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center